The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Neogenomics Inc shares valued at $112,322 were purchased by Sherman Jeffrey Scott on Aug 06 ’25. At $5.62 per share, Sherman Jeffrey Scott acquired 20,000 shares. The insider’s holdings grew to 188,332 shares worth approximately $1.03 million following the completion of this transaction.
Also, Zook Anthony P. purchased 17,900 shares, netting a total of over 99,954 in proceeds. Following the buying of shares at $5.58 each, the insider now holds 38,066 shares.
Before that, Kelly Michael Aaron had added 5,000 shares to its account. In a trade valued at $38,000, the Director bought Neogenomics Inc shares for $7.60 each. Upon closing the transaction, the insider’s holdings increased to 5,000 shares, worth approximately $27450.0.
As published in a research note from BTIG Research on July 30, 2025, Neogenomics Inc [NEO] has been rated down from a Buy to a Neutral. Analysts at William Blair downgraded the stock from ‘”an Outperform”‘ to ‘”a Mkt perform”‘ outlook in a report released in late July. As of May 15, 2025, Guggenheim has initiated its “Neutral” rating for NEO. Earlier on April 30, 2025, Leerink Partners downgraded its rating. Their new recommendation was “a Market perform” for NEO stock which previously was a “an Outperform”.
Analyzing NEO Stock Performance
On last trading session, Neogenomics Inc [NASDAQ: NEO] plunged -2.31% to $5.49. The stock’s lowest price that day was $5.37, but it reached a high of $5.675 in the same session. During the last five days, there has been a surge of approximately 7.65%. Over the course of the year, Neogenomics Inc shares have dropped approximately -68.03%.
Is Neogenomics Inc subject to short interest?
Stocks of Neogenomics Inc saw a sharp steep in short interest on 2025-07-15 dropping by 37829.0 shares to 4.27 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 4.31 million shares. A decline of -0.89% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 2.18 of the overall float, the days-to-cover ratio (short ratio) decline to 2.18.
Which companies own the most shares of Neogenomics Inc (NEO)?
In terms of Neogenomics Inc share price expectations, FactSet research, analysts set an average price target of 8 in the next 12 months, up nearly 42.35% from the previous closing price of $5.62. Analysts anticipate Neogenomics Inc stock to reach 11 by 2025, with the lowest price target being 8. In spite of this, 8 analysts ranked Neogenomics Inc stock as Buy at the end of 2025.
